Literature DB >> 18369725

Alterations in body composition in acromegaly.

Laurence Katznelson1.   

Abstract

Acromegaly is a condition characterized by growth hormone (GH) and insulin-like growth factor-1 (IGF-1) hypersecretion, and is associated with boney overgrowth, and soft tissue abnormalities due to anabolic, lipolytic, and sodium retaining actions of GH. GH and IGF-1 excess is associated with alterations in body composition, including an increase in body water and lean body mass, and a reduction in body fat. Achievement of biochemical control of the disease results in a reduction in body water and fat-free mass, and an increase in body fat. BMD is generally increased in acromegaly, though the anabolic effect of GH excess on bone is reduced, if not negated, by the presence of hypogonadism, particularly with regard to the trabecular compartment. Further studies are necessary to determine the effect of long-term biochemical control on bone density in subjects with acromegaly.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18369725     DOI: 10.1007/s11102-008-0104-8

Source DB:  PubMed          Journal:  Pituitary        ISSN: 1386-341X            Impact factor:   4.107


  59 in total

Review 1.  Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects.

Authors:  Jens Møller
Journal:  Growth Horm IGF Res       Date:  2003 Apr-Jun       Impact factor: 2.372

2.  Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function.

Authors:  Marek Bolanowski; Jacek Daroszewski; Marek Medraś; Beata Zadrozna-Sliwka
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

Review 3.  Effects of growth hormone on glucose and fat metabolism in human subjects.

Authors:  Jens O L Jørgensen; Louise Møller; Morten Krag; Nils Billestrup; Jens S Christiansen
Journal:  Endocrinol Metab Clin North Am       Date:  2007-03       Impact factor: 4.741

4.  Bone marrow adipocytes: a neglected target tissue for growth hormone.

Authors:  Evelien F Gevers; Nigel Loveridge; Iain C A F Robinson
Journal:  Endocrinology       Date:  2002-10       Impact factor: 4.736

Review 5.  Growth hormone as an early embryonic growth and differentiation factor.

Authors:  Esmond J Sanders; Steve Harvey
Journal:  Anat Embryol (Berl)       Date:  2004-11

6.  Bone mineral density in acromegaly: the effect of gender, disease activity and gonadal status.

Authors:  Alfredo Scillitani; Claudia Battista; Iacopo Chiodini; Vincenzo Carnevale; Saverio Fusilli; Enrica Ciccarelli; Massimo Terzolo; Giuseppe Oppizzi; Maura Arosio; Maurizio Gasperi; Giorgio Arnaldi; Annamaria Colao; Roberto Baldelli; Maria Rosaria Ghiggi; Daniela Gaia; Carolina Di Somma; Vincenzo Trischitta; Antonio Liuzzi
Journal:  Clin Endocrinol (Oxf)       Date:  2003-06       Impact factor: 3.478

7.  Myostatin is a skeletal muscle target of growth hormone anabolic action.

Authors:  Wei Liu; Scott G Thomas; Sylvia L Asa; Nestor Gonzalez-Cadavid; Shalendar Bhasin; Shereen Ezzat
Journal:  J Clin Endocrinol Metab       Date:  2003-11       Impact factor: 5.958

8.  Body composition in active acromegaly during treatment with octreotide: a double-blind, placebo-controlled cross-over study.

Authors:  T B Hansen; J Gram; P Bjerre; C Hagen; J Bollerslev
Journal:  Clin Endocrinol (Oxf)       Date:  1994-09       Impact factor: 3.478

9.  Factors associated with bone metabolism in acromegalic patients: hypogonadism and female gender.

Authors:  N B Tütüncü; T Erbaş
Journal:  Exp Clin Endocrinol Diabetes       Date:  2004-06       Impact factor: 2.949

10.  Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis.

Authors:  Toshimasa Yamauchi; Junji Kamon; Hironori Waki; Yasushi Imai; Nobuhiro Shimozawa; Kyouji Hioki; Shoko Uchida; Yusuke Ito; Keisuke Takakuwa; Junji Matsui; Makoto Takata; Kazuhiro Eto; Yasuo Terauchi; Kajuro Komeda; Masaki Tsunoda; Koji Murakami; Yasuyuki Ohnishi; Takeshi Naitoh; Kenichi Yamamura; Yoshito Ueyama; Philippe Froguel; Satoshi Kimura; Ryozo Nagai; Takashi Kadowaki
Journal:  J Biol Chem       Date:  2002-11-12       Impact factor: 5.157

View more
  26 in total

1.  Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.

Authors:  Claire Briet; Mirela Diana Ilie; Emmanuelle Kuhn; Luigi Maione; Sylvie Brailly-Tabard; Sylvie Salenave; Bertrand Cariou; Philippe Chanson
Journal:  Endocrine       Date:  2018-11-05       Impact factor: 3.633

2.  Static and dynamic balances of patients with acromegaly and impact of exercise on balance.

Authors:  Ozlem Haliloglu; Nuri Topsakal; Filiz Camliguney; Ozge Polat Korkmaz; Serdar Sahin; Birol Cotuk; Pinar Kadioglu; Oya Erkut
Journal:  Pituitary       Date:  2019-10       Impact factor: 4.107

Review 3.  Altered structure and function of adipose tissue in long-lived mice with growth hormone-related mutations.

Authors:  Justin Darcy; Samuel McFadden; Andrzej Bartke
Journal:  Adipocyte       Date:  2017-03-21       Impact factor: 4.534

4.  Adrenal lesions in acromegaly: do metabolic aspects and aryl hydrocarbon receptor interacting protein gene have a role? Evaluation at baseline and after long-term follow-up.

Authors:  F Ceccato; G Occhi; N M Albiger; S Rizzati; S Ferasin; G Trivellin; F Mantero; C Scaroni
Journal:  J Endocrinol Invest       Date:  2010-07-01       Impact factor: 4.256

5.  Three-dimensional facial analysis in acromegaly: a novel tool to quantify craniofacial characteristics after long-term remission.

Authors:  M A E M Wagenmakers; S H P P Roerink; T J J Maal; R H Pelleboer; J W A Smit; A R M M Hermus; S J Bergé; R T Netea-Maier; T Xi
Journal:  Pituitary       Date:  2015-02       Impact factor: 4.107

6.  Targeted deletion of somatotroph insulin-like growth factor-I signaling in a cell-specific knockout mouse model.

Authors:  Christopher J Romero; Yewade Ng; Raul M Luque; Rhonda D Kineman; Linda Koch; Jens C Bruning; Sally Radovick
Journal:  Mol Endocrinol       Date:  2010-03-08

7.  Altered somatotroph feedback regulation improves metabolic efficiency and limits adipose deposition in male mice.

Authors:  Christopher J Romero; Andrew Wolfe; Yi Ying Law; ChenChen Z Costelloe; Ryan Miller; Fredric Wondisford; Sally Radovick
Journal:  Metabolism       Date:  2015-12-08       Impact factor: 8.694

Review 8.  The GH/IGF-1 axis in ageing and longevity.

Authors:  Riia K Junnila; John J Kopchick; Edward O List; Darlene E Berryman; John W Murrey
Journal:  Nat Rev Endocrinol       Date:  2013-04-16       Impact factor: 43.330

Review 9.  Leptin receptor modulation of adiposity and fertility.

Authors:  Davelene Israel; Streamson Chua
Journal:  Trends Endocrinol Metab       Date:  2009-10-23       Impact factor: 12.015

10.  Age-related changes in body composition of bovine growth hormone transgenic mice.

Authors:  Amanda J Palmer; Min-Yu Chung; Edward O List; Jennifer Walker; Shigeru Okada; John J Kopchick; Darlene E Berryman
Journal:  Endocrinology       Date:  2008-10-23       Impact factor: 4.736

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.